FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Complete Response on Rocket Gene Therapy

[ Price : $8.95]

FDA issues Rocket Pharmaceuticals a complete response letter on its BLA for gene therapy Kresladi (marnetegragene autotemcel; marn...

Shorla Oncology Breast/Ovarian Cancer Drug OKd

[ Price : $8.95]

FDA approves a Shorla Oncology NDA for Tepylute (thiotepa), a ready-to-dilute formulation for treating breast and ovarian cancer.

Promising Myasthenia Gravis Trial Data: J&J

[ Price : $8.95]

Johnson & Johnson reports positive data from its Phase 3 Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia...

Praise for Biological Labeling Draft Guidance

[ Price : $8.95]

The Biosimilars Council and Biosimilars Forum praise a revised FDA draft guidance on biosimilar promotional labeling.

Dog Heartworm Prevention Drug Guidance

[ Price : $8.95]

FDA publishes a guidance with additional details on earlier guidances on evaluating the effectiveness of drugs indicated to treat ...

6 Observations in Cipla FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at a Goa, India, Cipla drug manufacturing facility.

FDA Opening Office in Rwanda

[ Price : $8.95]

FDA associate commissioner for global policy and strategy Mark Abdoo says the agency will support the African Medicines Agency thr...

FDA Modifies CAR T Cell REMS

[ Price : $8.95]

FDA modifies the REMS for CAR T cell products to ease the burden on hospitals and their clinics.

Draft Guide on Diversity Action Plans

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Diversity Action Plans to Improve Enrollment of Participant...

Guide on Priority Zoonotic Drug Designations

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Priority Zoonotic Animal Drug Designation and Review Proces...